NANO-CAN — NANOFTONIC CANCER FOR FIGHTING CANCER (Q2023743)
Jump to navigation
Jump to search
Project Q2023743 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NANO-CAN — NANOFTONIC CANCER FOR FIGHTING CANCER |
Project Q2023743 in Italy |
Statements
2,821,849.8 Euro
0 references
3,762,466.4 Euro
0 references
75.0 percent
0 references
1 January 2018
0 references
31 December 2020
0 references
CERICT SCRL - CENTRO REGIONALE INFORMATION COMMUNICATION TECHNOLOGY
0 references
TEORESI S.P.A
0 references
BIOPOX S.R.L
0 references
REGIONE CAMPANIA
0 references
TECNO-BIOS SRL
0 references
L'OBIETTIVO PRINCIPALE RIGUARDA LO SVILUPPO DI PIATTAFORME INNOVATIVE PER LA TERANOSTICA IN VIVO BASATE SU TECNOLOGIA AVANZATA IN FIBRA OTTICA, ATTRAVERSO UN SOLO DISPOSITIVO, OTTENUTO MEDIANTE INTEGRAZIONE DI DIVERSI PROBE MULTIFUNZIONALI IN FIBRA, INGEGNERIZZATI PER LA SPECIFICA APPLICAZIONE E INTEGRATI IN AGHI MEDICALI. SARÃ POSSIBILE AVERE UN UNICO STRUMENTO CAPACE DI EFFETTUARE CONTEMPORANEAMENTE DIAGNOSI E TERAPIA, OSSIA TERANOSTICA, IN VIVO, ALL'INTERNO DEL CORPO DEL PAZIENTE. (Italian)
0 references
THE MAIN OBJECTIVE CONCERNS THE DEVELOPMENT OF INNOVATIVE PLATFORMS FOR IN VIVO THERANOSTICS BASED ON OPTICAL FIBRE ADVANCED TECHNOLOGY, THROUGH A SINGLE DEVICE, WHICH IS ACHIEVED THROUGH THE INTEGRATION OF SEVERAL DIFFERENT FIBRES OF FIBRE, ENGINEERED FOR THE SPECIFIC APPLICATION AND INTEGRATED IN MEDICAL NEEDLES. IT WILL BE POSSIBLE TO HAVE A SINGLE INSTRUMENT CAPABLE OF SIMULTANEOUSLY DIAGNOSING AND TREATING THE PATIENT, IN VIVO, WITHIN THE BODY OF THE PATIENT. (English)
0 references
L’OBJECTIF PRINCIPAL EST LE DÉVELOPPEMENT DE PLATES-FORMES TERANOSTIC INNOVANTES IN VIVO BASÉES SUR LA TECHNOLOGIE DE POINTE DE LA FIBRE OPTIQUE, À TRAVERS UN DISPOSITIF UNIQUE, OBTENU PAR L’INTÉGRATION DE PLUSIEURS SONDES À FIBRES MULTIFONCTIONNELLES, CONÇUES POUR L’APPLICATION SPÉCIFIQUE ET INTÉGRÉES DANS DES AIGUILLES MÉDICALES. IL SERA POSSIBLE D’AVOIR UN SEUL INSTRUMENT CAPABLE DE FAIRE SIMULTANÉMENT DIAGNOSTIC ET THÉRAPIE, I.E. TERANOSTIC, IN VIVO, À L’INTÉRIEUR DU CORPS DU PATIENT. (French)
14 December 2021
0 references
Identifiers
B51C17000050007
0 references